The Dubs might not have the same strength in their numbers that they once boasted. Curry and Draymond Green’s legs might not ...

Endpoints Weekly covers Q1 earnings from major pharma companies, with focus on tariff concerns. FDA's Makary discusses new rare disease pathway, and HuidaGene reports first brain CRISPR treatment.

A team was able to edit the DNA of Lactobacillus strains directly without a template from other organisms. This technique is indistinguishable from natural variation and enabled the researchers to ...

It was easier to fret about the ongoing climate tragedy … than to let my attention lie fallow, occupied only by a hyperawareness of myself, in prison,” writes Michael Fischer. “I read about ...

We expect investors to focus on the sales numbers of CRISPR Therapeutics’ CRSP sole-marketed product, Casgevy, and other ...

Sickle cell has been overlooked for far too long. Fortunately, there are new breakthroughs in sickle cell treatment that you ...

Prime Medicine’s modular editing tech may lower off-target risk, but key data and funding milestones remain ahead. Find out ...

The CRISPR company is laying off about a third of its employees and stopping work on an experimental lupus treatment in a bid ...

Genomics company, Integrated DNA Technologies, is rewriting the future of genomics, pioneering new innovations in a bold move ...

The blood-brain barrier border protects the brain by regulating the flow of molecules, peptides, and cells, but it also keeps out many therapeutics. Now, researchers have harnessed the power of a ...

Preetika Rana is an award-winning reporter for The Wall Street Journal in San Francisco with experience reporting from six countries. Her articles have shaped business practices, opened government ...

The company is hoping longer follow-up will deliver enough positive trial data on its CRISPR T-cell therapies for blood ...